Related by context. Frequent words. (Click for all words.) 71 VEGFR2 inhibitor 65 multi kinase inhibitor 65 refractory chronic lymphocytic 63 R sorafenib tablets 63 liposomal formulation 63 Panzem R NCD 62 Phase Ib IIa 62 Panzem R 62 IMC #B 62 Trofex 62 Belimumab 61 Phase Ib II 61 ThermoDox R 61 orally bioavailable 61 YOUR LOCAL ANIMAL SHELTER 61 Daclizumab 61 BiTE R 61 Sapacitabine 61 forodesine 61 recurrent glioblastoma multiforme 61 metastatic colorectal 60 Laquinimod 60 HGS ETR2 60 Tesetaxel 60 phase Ib 60 immune modulating 60 cutaneous T 60 Zoraxel 60 metastatic hormone refractory 60 systemically administered 60 supplemental biologics 60 ongoing Phase 1b 60 metastatic castration resistant 60 MKC# 60 Pralatrexate 60 Genasense ® oblimersen 60 metastatic castrate resistant 59 Dapagliflozin 59 pertuzumab 59 CCR5 antagonist 59 HGS ETR1 59 Initiates Phase II 59 superficial bladder cancer 59 phase IIb clinical 59 administered subcutaneously 59 Voreloxin 59 proteasome inhibitor 59 Dasatinib 59 IIa trial 59 optical biosensors 59 Mipomersen 58 opioid induced bowel dysfunction 58 ATL# [001] 58 clinically contraindicated 58 histone deacetylase HDAC inhibitor 58 CR# vcMMAE 58 diagnosed Ph + 58 CYC# 58 Golimumab 58 inhaled formulation 58 transcriptase inhibitor NNRTI 58 TACI Ig 58 pegylated interferon alfa 2a 58 peripherally acting 58 angiogenesis inhibitor 58 2 methoxyestradiol 58 HuMax EGFr 58 factor G CSF 58 huC# DM4 57 Eculizumab 57 SUCCEED trial 57 Ixempra 57 Meets Primary Endpoint 57 mTOR inhibitor 57 SAR# [004] 57 BAY #-# 57 GLPG# 57 unresectable locally advanced 57 Pivotal Phase III 57 Presents Positive 57 Vandetanib 57 Phase Ib clinical trials 57 Factor VIIa 57 Brentuximab vedotin 57 PD LID 57 preclinical efficacy 57 Blinatumomab 57 vascular disrupting agent 57 Edurant 57 HMG CoA reductase inhibitors 57 immunomodulator 57 Allovectin 7 ® 57 hormone refractory 57 DXL# 57 investigational oral 56 L Annamycin 56 Elesclomol 56 Roflumilast 56 registrational trial 56 INTERCEPT red 56 Hydroxyurea